Issues for clinical drug development in neurodegenerative diseases

Drugs

Volumn 65, Issue 17, 2005, Pages 2463-2479

  Dib, Michel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E4; BETA INTERFERON; BIOCHEMICAL MARKER; CHOLESTEROL; CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; GLATIRAMER; LAMOTRIGINE; NEUROPROTECTIVE AGENT; NICOTINIC AGENT; PARKIN; PLACEBO; PROTEIN NOGO; RILUZOLE; SELEGILINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TOCOPHEROL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BASAL GANGLION; CEREBROSPINAL FLUID ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; DISEASE MARKER; DOPAMINE UPTAKE; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; EVALUATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MACHADO JOSEPH DISEASE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RATING SCALE; REVIEW; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TREATMENT PLANNING; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MUS MUSCULUS;

EID: 28144456412     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565170-00004     Document Type: Review

References (94)

1. Hauw JJ, Dubois B, Verny M, et al. La maladie d'Alzheimer. Paris: Editions John Libbey Eurotext - collection pathologie science formation, 1997
2. Sobue G, Sahabashi KM, Takahashi A, et al. Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. Neurology 1983; 33: 654-7
3. Hedreen JC, Peyser CE, Folstein SE, et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991; 133: 257-61
4. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegenera-tion in multiple sclerosis. Ann Neurol 2002; 52: 650-3
5. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 388-96
6. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-7
7. Dib M. Amyotrophic lateral sclerosis: progress and prospects for treatment. Drugs 2003; 63 (3): 289-310
8. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54: 452-8
9. Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609-15
10. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91
11. Validation of surrogate from endpoint multiple trials. National Institutes of Health, 1998 [online]. Available from URL: http:// www4.od.nih.gov/biomarkers [Accessed 2005 Sep 26]
12. Desnuelle C, Dib M, Garrel C, et al. A double-blind, placebo-controlled randomized clinical trial of ́-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis: ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 9-18
13. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-8
14. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-45
15. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-103
16. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease: perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111: 247-72
17. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44: 17-26
18. Tapiola T, Pirttila T, Mikkonen M, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000; 280: 119-22
19. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25-30
20. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995; 38: 649-52
21. Hock C, Golombowski S, Naser W, et al. Increased levels of Tau protein in cerebrospinal fluid of patients with Alzheimer's disease: correlation with degree of cognitive impairment. Ann Neurol 1995; 37: 414-5
22. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995; 45: 788-93
23. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998; 64: 298-305
24. Poser S, Zerr I, Schroeter A, et al. Clinical and differential diagnosis of Creutzfeldt-Jakob disease. Arch Virol Suppl 2000; 16: 153-9
25. Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 71: 33-9
26. Huang N, Marie SK, Livramento JA, et al. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 2003 Aug 12; 61: 354-7
27. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 7-20
28. Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108: 1-8
29. Sormani MP, Bruzzi P, Comi G, et al. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58: 417-21
30. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7
31. Wang D, Chalk JB, Rose SE, et al. MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer's disease and normal aging. Magn Reson Imaging 2002; 20: 41-8
32. Jack Jr CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600
33. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-11
34. Brooks DJ. PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol 1997; 6: 69-87
35. Piccini P. Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 2004; 17: 459-66
36. Stoof JC, Winogrodzka A, van Muiswinkel FL, et al. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol 1999; 375: 75-86
37. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61
38. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101
39. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progres-sion of Parkinson's disease. N Engl J Med 2004; 351: 2498-508
40. LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology 2004; 63 Suppl. 2: S23-31
41. Cesaro P. Neuron transplantation and Parkinson disease. Rev Neurol 2002; 158 Spec. No. 1: S142-3
42. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson's disease. Florham Park (NJ): Macmillan Health Care Information, 1987: 153-63
43. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-42
44. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
45. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203
46. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551-6
47. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54
48. Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad Sci 1984; 436: 347-60
49. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG) [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39: 285-94
50. PRISMS (Prevention of Relapses and disability by Interferon-β 1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised, double-blind, placebo-controlled study of interferon-β 1a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998; 352: 1498-504
51. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999; 67: 451-6
52. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57: 1969-75
53. Martinelli-Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003; 9: 349-55
54. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003; 9: 585-91
55. Ford C, Johnson K, Brooks B, et al. Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over ten years [abstract]. Mult Scler 2003; 9 Suppl. 1: S120
56. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis: Northeast ALS Consortium. Neurology 2003; 61: 456-64
57. Traynor BJ, Zhang H, Shefner JM, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004; 63: 1933-5
58. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83
59. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease: Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602-7
60. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191-6
61. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
62. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 2000; 6 (22 Suppl.): S1139-44
63. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15
64. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8
65. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia: Clinical Progression of Dementia Study Group. N Engl J Med 2001; 344: 1111-6
66. Diesfeldt HFA, van Houte LR, Moerkens RM. Duration of survival in senile dementia. Acta Psychiatr Scand 1986; 73: 366-71
67. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347 (9013): 1425-31
68. Forbes RB, Colville S, Cran GW, et al. Scottish Motor Neurone Disease Register. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. J Neurol Neurosurg Psychiatry 2004; 75: 1753-5
69. Couratier P, Druet-Cabanac M, Truong CT, et al. Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS. Rev Neurol 2000; 156: 357-63
70. Turner MR, Bakker M, Sham P, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15-21
71. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000. J Neurol 2003; 250: 473-9
72. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64: 87-93
73. Rosen DR, Sapp P, O'Regan J, et al. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromo-some 21 microsatellite DNA markers. Am J Med Genet 1994; 51: 61-9
74. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995; 676: 25-40
75. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-57
76. Maragakis NJ, Jackson M, Ganel R, et al. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003; 338: 107-10
77. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-50
78. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A random-ized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437-45
79. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656-61
80. Bates GP, Mangiarini L, Mahal A, et al. Transgenic models of Huntington's disease. Hum Mol Genet 1997; 6: 1633-7
81. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523-7
82. Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 358-65
83. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 Aug 13; 261 (5123): 921-3
84. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-7
85. Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003; (3): CD001244
86. Lutsep HL, Clark WM. Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2001; 1: 13-8
87. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 2004; 7: 351-69
88. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196-203
89. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis: rhCNTF ALS Study Group. Ann Neurol 1996; 39: 256-60
90. Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf 2004; 3: 525-34
91. Ince PG, Shaw PJ, Slade JY, et al. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol 1996; 92: 395-403
92. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-9
93. Tanaka Y, Hanyu H, Sakurai H, et al. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2003; 16: 119-25
94. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med 2002; 8: 319-23